866-997-4948(US-Canada Toll Free)

Oropharyngeal Cancer - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : May 2015

Category :

Cancer

No. of Pages : 79 Pages


Global Markets Directs, Oropharyngeal Cancer Pipeline Review, H1 2015, provides an overview of the Oropharyngeal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oropharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Oropharyngeal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Oropharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Oropharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Oropharyngeal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Oropharyngeal Cancer - Overview 7
Pipeline Products for Oropharyngeal Cancer - Comparative Analysis 8
Oropharyngeal Cancer - Therapeutics under Development by Companies 9
Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 10
Oropharyngeal Cancer - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Oropharyngeal Cancer - Products under Development by Companies 14
Oropharyngeal Cancer - Products under Investigation by Universities/Institutes 15
Oropharyngeal Cancer - Companies Involved in Therapeutics Development 16
Advaxis, Inc. 16
AstraZeneca PLC 17
AVEO Pharmaceuticals, Inc. 18
Merck & Co., Inc. 19
Novartis AG 20
Serina Therapeutics, Inc. 21
VLPbio 22
Oropharyngeal Cancer - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ADXS-HPV - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alpelisib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy for HPV Associated Cancers - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ficlatuzumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HNVax - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
olaparib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pembrolizumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SER-203 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Oropharyngeal Cancer - Recent Pipeline Updates 53
Oropharyngeal Cancer - Dormant Projects 77

Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79

List of Table


Number of Products under Development for Oropharyngeal Cancer, H1 2015 7
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H1 2015 16
Oropharyngeal Cancer - Pipeline by AstraZeneca PLC, H1 2015 17
Oropharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 18
Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2015 19
Oropharyngeal Cancer - Pipeline by Novartis AG, H1 2015 20
Oropharyngeal Cancer - Pipeline by Serina Therapeutics, Inc., H1 2015 21
Oropharyngeal Cancer - Pipeline by VLPbio, H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Oropharyngeal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 53
Oropharyngeal Cancer - Dormant Projects, H1 2015 77

List of Chart


Number of Products under Development for Oropharyngeal Cancer, H1 2015 7
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 24
Number of Products by Stage and Top 10 Targets, H1 2015 25
Number of Products by Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Top 10 Routes of Administration, H1 2015 28
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29
Number of Products by Top 10 Molecule Types, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *